Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...
Breast cancer pathogenesis is influenced by various molecular and environmental risk factors. It begins through the mutation of oncogenes, tumor suppressor genes, and dysregulation of key cell ...
New agreement enables both companies to fuel a broad and innovative pipeline of 212 Pb-Radio-DARPin candidates, bringing the total number of programs up to ten Expanded partnership highlights the ...
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial Overall, 210 ...
Highly comparable biodistribution profiles of Radio-DARPin candidates labeled with imaging isotopes 177Lu or 203Pb allows for rapid expansion of ...
Menin inhibitors reshape AML care, boosting targeted options for KMT2A- and NPM1-mutant disease, with promising frontline ...
or on the link below. Novel approaches in molecular imaging and targeted therapeutics are transforming the management of renal cell carcinoma (RCC) and urothelial carcinoma (UC). This review focuses ...
Combination therapy is essentially a one-two punch at cancer—sometimes with multiple punches. For people with lung cancer, it ...
Molecular Partners and Orano Med expand collaboration to develop ten 212Pb-Radio-DARPin therapy candidates, initiating clinical trials in 2025. Molecular Partners AG and Orano Med have expanded their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results